Trials / Terminated
TerminatedNCT04487405
A Multivariate Index Assay for Ovarian Cancer Risk Assessment in Women With Adnexal Mass and High-Risk Germline Variants
- Status
- Terminated
- Phase
- —
- Study type
- Observational
- Enrollment
- 721 (actual)
- Sponsor
- Aspira Women's Health · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this project is to validate the sensitivity, specificity, positive predictive value and negative predictive values of the AMRA blood test for assessing risk of cancer in women at high risk for ovarian cancer, due to the presence of a symptomatic adnexal mass.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | OVAnex | OVAnex is a multivarite index assay assessing ovarian cancer risk |
Timeline
- Start date
- 2020-06-25
- Primary completion
- 2023-12-15
- Completion
- 2023-12-15
- First posted
- 2020-07-27
- Last updated
- 2023-12-26
Locations
9 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT04487405. Inclusion in this directory is not an endorsement.